Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib have?

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib has 418 citations in the OpenAlex counts ScholarIQ stores.

When was Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib published?

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib has 2019 year in the ScholarIQ index.

What is the open-access status of Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib?

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib has bronze oa status in the ScholarIQ index.

What is the DOI of Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib?

The DOI for Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib is on the source record.

What is the PMID of Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib?

The PMID for Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib is on the source record.

What is the OpenAlex record for Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib?

The OpenAlex for Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib is on the source record.